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Purpose The main purpose of the present study is to determine if the circadian rhythms 
present in the human bone marrow are likely to influence 3’- deoxy- 3’-[18F] Fluorothymidine 
(18F-FLT) uptake in the same organ. The 18F-FLT is a Thymidine analogous proliferation agent. 
The relatively high physiological uptake of this tracer in the bone marrow diminishes the 
Tumor/Background (T/B) ratio, decreasing the detection accuracy of PET/CT and possibly 
affecting SUV quantifications. Methodology The present study was of level I, descriptive 
correlational. The methodology was a bibliographic research in the search motors PubMed, 
Science Direct, among others, in a population of scientific articles having the key words related 
with the present study. The articles found were analyzed in terms of their global quality and 
methodologies and exclusion factors, such as publication Impact Factor (IF), were applied to 
limit the population. Results The most relevant finding was the articles describing that the 
cytosolic enzyme Thymidine Kinase I (TK1) follows a marked circadian variation, with its 
acrophase (highest concentration) at the bone marrow occurring at 16.00h or 10 HALO (hours 
after light onsent). TK1 is responsible for intracellular retention of 18F-FLT, similarly to the way 
hexokinase is responsible for the retention of 3’- deoxy- 3’- [18F] Fluorodeoxyglucose (18F-
FDG), and for reduction of mielotoxicity of the oncostatic agents Fluorouridine (FdUdr) and 
Azido Thymidine (AZT). This circadian variation of TK1 is the rationale behind 
chronomodulated chemotherapy treatments using the referred oncostatic agents. In these 
treatments the drug is administered at times of the day when TK1 activity is low, reducing the 
mielotoxicity and allowing higher doses of these agents to be administered with therefore 
better survival rates. Using published articles in different fields it was possible to identify the 
genes and gene mediators responsible for the circadian regulation of TK1. Conclusions The 
data collected suggests that the physiological uptake of the 18F-FLT in the bone marrow most 
likely follows a circadian pattern, due to the marked circadian rhythm presented both by TK1 
and cell cycle progression of healthy cells. Hence it is possible that differences on the SUV 
quantifications measured at various times of day do occur. These findings are especially 
important in cases of treatment assessment scans. The circadian 18F-FLT amplitude of 
variation at peripheral organs should be quantified in order to aid assessing the error margin 
of SUV calculations for this tracer. 
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